# EDGAR Filing Document

**Accession Number:** 0001650664
**File Stem:** 0001650664-26-000063
**Filing Date:** 2026-6
**Character Count:** 6421
**Document Hash:** 022254fc6ac85afca9edda00b0835d1d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001650664-26-000063.hdr.sgml**: 20260618

**ACCESSION NUMBER**: 0001650664-26-000063

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260617

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260618

**DATE AS OF CHANGE**: 20260618

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Editas Medicine, Inc.
- **CENTRAL INDEX KEY:** 0001650664
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 464097528
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37687
- **FILM NUMBER:** 261103146

**BUSINESS ADDRESS:**
- **STREET 1:** 11 HURLEY ST.
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02141
- **BUSINESS PHONE:** 617-401-9000

**MAIL ADDRESS:**
- **STREET 1:** 11 HURLEY ST.
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02141

?xml version='1.0' encoding='ASCII'? edit-20260617

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

_________________________________________________________________________________________

**FORM 8-K**

_________________________________________________________________________________________

**CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 17, 2026**

_________________________________________________________________________________________

**Editas Medicine, Inc.**

(Exact Name of Registrant as Specified in its Charter)

________________________________________________________________________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37687** | **46-4097528** |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

---

| | |
|:---|:---|
| **11 Hurley Street<br>Cambridge, Massachusetts** | **02141** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(617) 401-9000**

(Former Name or Former Address, if Changed Since Last Report)

_________________________________________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.0001 par value per share | EDIT | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.07.&nbsp;&nbsp;&nbsp;&nbsp;Submission of Matters to a Vote of Security Holders**

On June 17, 2026, Editas Medicine, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting"). The following is a summary of matters voted on at the 2026 Annual Meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.The Company's stockholders elected Bernadette Connaughton and Elliott Levy, M.D., to serve as Class I directors until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified. The results of the stockholders' vote with respect to the election of such Class I directors were as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| |  | **Votes For** |  | **Votes**<br>**Withheld** |  | **Broker**<br>**Non-Votes** |
| Bernadette Connaughton  | | 28,660,181 | | 10,789,549 | | 26,404,190 |
| Elliott Levy, M.D. | | 37,095,058 | | 2,354,672 | | 26,404,190 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.The Company's stockholders approved, on an advisory basis, the compensation paid to its named executive officers. The results of the stockholders' non-binding, advisory vote with respect to compensation paid to the Company's named executive officers were as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Votes For** |  | **Votes**<br>**Against** |  | **Votes**<br>**Abstaining** |  | **Broker**<br>**Non-Votes** |
| 32,914,258 |  | 6,322,885 |  | 212,587 |  | 26,404,190 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders' vote with respect to such ratification were as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Votes For** |  | **Votes**<br>**Against** |  | **Votes**<br>**Abstaining** |  | **Broker**<br>**Non-Votes** |
| 64,686,839 |  | 774,471 |  | 392,610 |  | 0 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | EDITAS MEDICINE, INC. | EDITAS MEDICINE, INC. |
| Date: | June 18, 2026 | By: | /s/ Gilmore O'Neill |
|  |  |  | Gilmore O'Neill<br>President & Chief Executive Officer |

---